Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 5, 2020
Daily News
October 5, 2020
- Nihon Chouzai’s Standard Formulary Service Fully Up and Running
October 5, 2020
- Axcelead, Kyowa Kirin Join Forces to Develop Small-Molecule Drugs
October 5, 2020
- Scrap Income Limit for Fertility Treatment Subsidies: LDP Lawmakers
October 5, 2020
- Lilly’s Baqsimi Hits Japan Market, 1st Glucagon Nasal Powder
October 5, 2020
- MHLW to Draft Guidelines by Year-End on Use of Patient Registry Data in Drug Filing
October 5, 2020
- AstraZeneca’s COVID-19 Vaccine Trial Resumes in Japan
October 5, 2020
- Chugai Seeks Label Expansion for FoundationOne as CDx for Pemigatinib, Larotrectinib
October 5, 2020
- Kyowa Kirin Commences Japan PII of Zandelisib for Indolent B-Cell Non-Hodgkin’s Lymphoma
October 5, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…